Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan vs Norditropin in Chinese children with growth hormone deficiency
NCT04970654Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Height Velocity at 52 weeks. Started Jul 2021; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04970654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970654.